Vivek Subbiah: This review delves into the evolution of basket trials in cancer drug development

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:

“Delighted to share our publication in the American Cancer Society Journal, ‘Revolutionizing cancer drug development: Harnessing the potential of basket trials’.

Basket trials for Tissue-Agnostic Precision Medicine. The landscape of cancer therapy has been transformed by advances in clinical next-generation sequencing, genomically targeted therapies and immunotherapies.

Well-designed clinical trials and efficient clinical trial conduct are crucial for advancing our understanding of cancer, improving patient outcomes, and identifying personalized treatments. Basket trials have emerged as one of the efficient modern clinical trial designs that evaluate the efficacy of these therapies across multiple cancer types based on specific molecular alterations or biomarkers, irrespective of histology or anatomic location.

This review delves into the evolution of basket trials in cancer drug development, highlighting their potential prospects and current obstacles.”

For details, click here.
Source: Vivek Subbiah/LinkedIn